Bemarituzumab (FUT8-KO)

Product Description: Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa[1].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Xiang H, et al., Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021 Jan-Dec;13(1):1981202.

Molecular Weight: N/A

Compound Purity: 99.74

Research Area: Cancer

Target: FGFR;Interleukin Related

• SKU: MEXHY-P99010A-1
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-P99010A-1
• Package Unit: 1 mg
• Quantity Unit: STK
• Conjugate: Unconjugated